Cantor Fitzgerald keeps Neutral rating for Amgen stock

Published on 10/06/2026 at 12:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Scotiabank raised its target to USD 500 on September 29, 2026. Amgen stock costs EUR 361.58 on October 6, 2026 after EUR 359.03, plus 0.71 percent.

Architektonischer 3D-Render eines modernen Biopharma-Gebäudes mit Glasfassade und gepflegter Grünanlage — Amgen Inc. (ISIN US0311621009) passend visualisiert als architektonischer Render einer modernen Biopharma-Forschungsanlage, Illustration mit AI erstellt.

Amgen stock (ISIN US0311621009) was trading at EUR 361.58 at Lang & Schwarz on October 6, 2026 at 12:49 p.m. CEST, up 0.71 percent from the EUR 359.03 prior close. On October 5, 2026, Investing.com reported that Cantor Fitzgerald reiterated a Neutral rating and a USD 400.00 price target. The latest call puts the analyst debate close to the current USD valuation on Nasdaq.

Dazodalibep reaches a key trial goal

Amgen said on September 22, 2026 that its Phase 3 OASIZ 301 study of dazodalibep met its primary endpoint at Week 48. The company reported statistically significant and clinically meaningful improvement in systemic disease activity measured by the EULAR Sjogren's Syndrome Disease Activity Index.

The same release said improvements appeared by Week 4 and continued through Week 48. Amgen expects the related Phase 3 OASIZ 303 study to complete in the fourth quarter of 2026, keeping the autoimmune pipeline central to the stock story.

Second-quarter numbers beat consensus

MarketBeat reported that Amgen generated USD 10.05 billion in revenue in the second quarter of 2026, versus USD 9.43 billion consensus. Adjusted earnings per share reached USD 6.29, compared with USD 5.62 expected, while revenue rose 9.50 percent from the same quarter a year earlier.

That operating comparison gives the trial news a financial base. The company also set fiscal 2026 adjusted earnings-per-share guidance at USD 22.30-23.50, according to MarketBeat.

Amgen stock stays below its high

At Nasdaq, Amgen was at USD 402.98 at the October 5, 2026 close. The USD 217.5 billion market capitalization and the USD 288.00 to USD 447.03 52-week range show a large biotechnology company trading 9.85 percent below its yearly high, using the Nasdaq values.

The price contrast matters because Cantor Fitzgerald's USD 400.00 target sits below the October 5 Nasdaq close, while the USD 500.00 target from Scotiabank would be materially higher. Yahoo Finance listed Scotiabank's September 29, 2026 target change from USD 450.00 to USD 500.00 and retained its Sector Outperform view.

Price and pipeline set the next test

Amgen's near-term setup combines a clinical milestone with a measurable earnings beat. The next evidence point is detailed OASIZ 301 data at a future medical meeting, while OASIZ 303 is scheduled for completion in the fourth quarter of 2026.

Amgen was trading at EUR 361.58 at Lang & Schwarz on October 6, 2026 at 12:49 p.m. CEST, plus 0.71 percent versus the EUR 359.03 prior close. The further course of trading is shown by the continuously updated real-time quote of Amgen stock.